The Food and Drug Administration has approved Aegerion Pharmaceuticals’ request to market its first drug, a treatment for a rare inherited genetic disorder that can raise cholesterol to life-threatening levels. The condition is resistant to statins and other medications typically used to bring high cholesterol under control. The Cambridge biotech’s drug, Juxtapid, does carry a risk of liver toxicity, so it will come with a “black box” label — the FDA’s most serious warning level.
Aegerion wins approval for its first drug
Globe staff December 29, 2012
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢